NGL Fine Chem Ltd
Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]
- Market Cap ₹ 1,793 Cr.
- Current Price ₹ 2,900
- High / Low ₹ 3,602 / 1,261
- Stock P/E 28.1
- Book Value ₹ 587
- Dividend Yield 0.06 %
- ROCE 18.6 %
- ROE 17.4 %
- Face Value ₹ 5.00
Pros
- Company is expected to give good quarter
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88 | 96 | 100 | 114 | 153 | 152 | 258 | 318 | 278 | 339 | 368 | 501 | 575 | |
| Sales growth | +12% | +9% | +4% | +14% | -1% | +70% | +23% | -12% | +22% | +9% | +36% | +41% | |
| 73 | 74 | 74 | 92 | 121 | 130 | 178 | 249 | 243 | 285 | 333 | 421 | 480 | |
| Operating Profit | 15 | 22 | 25 | 22 | 32 | 22 | 80 | 68 | 35 | 54 | 35 | 80 | 95 |
| OPM % | 17% | 23% | 26% | 19% | 21% | 14% | 31% | 21% | 13% | 16% | 10% | 16% | 17% |
| 2 | 0 | 1 | 3 | 4 | 1 | 8 | 11 | 6 | 14 | 8 | 8 | 16 | |
| Interest | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 5 | 4 |
| Depreciation | 3 | 3 | 3 | 5 | 6 | 8 | 8 | 10 | 11 | 12 | 12 | 20 | 22 |
| Profit before tax | 13 | 18 | 23 | 18 | 28 | 12 | 78 | 67 | 27 | 54 | 28 | 63 | 85 |
| Tax % | 35% | 36% | 35% | 29% | 27% | 31% | 27% | 25% | 25% | 24% | 24% | 24% | |
| 8 | 11 | 15 | 13 | 20 | 8 | 57 | 50 | 20 | 41 | 21 | 48 | 64 | |
| EPS in Rs | 13.48 | 18.45 | 24.10 | 20.38 | 32.58 | 13.50 | 91.81 | 80.77 | 33.18 | 66.88 | 34.19 | 77.91 | 103.32 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 5% | 13% | 2% | 2% | 5% | 3% | 5% | 2% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 22% |
| TTM: | 41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 37% |
| TTM: | 209% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 1% |
| 3 Years: | 14% |
| 1 Year: | 109% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 14% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 30 | 41 | 56 | 69 | 89 | 96 | 151 | 200 | 219 | 260 | 279 | 326 | 360 |
| 13 | 14 | 23 | 27 | 27 | 28 | 16 | 30 | 32 | 34 | 78 | 123 | 127 | |
| 21 | 19 | 20 | 31 | 23 | 26 | 36 | 44 | 32 | 59 | 75 | 94 | 138 | |
| Total Liabilities | 67 | 78 | 102 | 129 | 142 | 154 | 207 | 277 | 287 | 356 | 435 | 545 | 628 |
| 17 | 24 | 25 | 56 | 61 | 68 | 64 | 89 | 88 | 86 | 143 | 164 | 291 | |
| CWIP | 1 | 2 | 16 | 3 | 0 | 0 | 12 | 6 | 26 | 46 | 50 | 95 | 0 |
| Investments | 2 | 3 | 6 | 6 | 9 | 11 | 29 | 29 | 39 | 54 | 60 | 39 | 39 |
| 46 | 49 | 55 | 63 | 73 | 75 | 102 | 153 | 133 | 171 | 183 | 247 | 298 | |
| Total Assets | 67 | 78 | 102 | 129 | 142 | 154 | 207 | 277 | 287 | 356 | 435 | 545 | 628 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | 8 | 10 | 22 | 9 | 20 | 27 | 14 | 35 | 20 | 32 | 43 | |
| -3 | -10 | -10 | -21 | -10 | -20 | -25 | -14 | -27 | -27 | -70 | -71 | |
| -4 | 2 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | 37 | 30 | |
| Net Cash Flow | 1 | 0 | -0 | 1 | -1 | -0 | 2 | -1 | 7 | -7 | 0 | 2 |
| Free Cash Flow | 5 | -2 | -8 | -1 | -6 | 6 | 10 | -15 | 5 | -8 | -41 | -43 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 80% | 68% | 70% | 128% | 50% | 110% | 60% | 45% | 121% | 62% | 111% | 73% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 107 | 123 | 110 | 89 | 79 | 63 | 53 | 74 | 86 | 97 | 82 | 95 |
| Inventory Days | 106 | 90 | 114 | 134 | 106 | 155 | 132 | 137 | 69 | 98 | 101 | 106 |
| Days Payable | 150 | 122 | 139 | 187 | 92 | 116 | 103 | 91 | 63 | 112 | 103 | 97 |
| Cash Conversion Cycle | 63 | 91 | 85 | 35 | 93 | 102 | 82 | 120 | 93 | 83 | 81 | 104 |
| Working Capital Days | 38 | 49 | 45 | 18 | 70 | 58 | 69 | 90 | 68 | 76 | 50 | 60 |
| ROCE % | 29% | 37% | 34% | 22% | 14% | 54% | 34% | 12% | 20% | 10% | 19% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Number of APIs in product portfolio APIs |
|
||||||
| Number of customers customers |
|||||||
| Stainless steel reactor capacity KL |
|||||||
| Top 10 customers as % of sales % |
|||||||
| Top 10 products as % of sales % |
|||||||
| Animal API share of revenue % |
|||||||
| Asia revenue share % |
|||||||
| Cumulative Greenfield expansion capex incurred INR crores |
|||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q2 and H1 FY27 earnings conference call uploaded on November 12, 2026.
- Announcement under Regulation 30 (LODR)-Investor Presentation
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Disclosure under Regulation 30A of LODR
- Board approved Q2 FY26 results and PPAs for 3.10 MW solar, 3.60 MW wind captive power.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Nov 2026PPT REC
-
Aug 2026PPT
-
May 2026Transcript PPT
-
Feb 2026PPT
-
Nov 2025Transcript PPT
-
Aug 2025PPT
-
May 2025Transcript PPT
-
Feb 2025PPT
-
Nov 2024Transcript PPT
-
Aug 2024PPT
-
Jun 2024Transcript PPT REC
-
May 2024PPT
-
Feb 2024PPT
-
Nov 2023Transcript
-
Nov 2023Transcript PPT REC
-
Aug 2023PPT
-
May 2023Transcript PPT
-
Feb 2023PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021PPT
-
Jun 2021Transcript PPT
-
Nov 2020Transcript
-
Jul 2020Transcript
-
Dec 2019Transcript
Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.
Product Profile:[3][4]
NGL Fine-Chem offers 45 APIs (43 veterinary and 2 human APIs), 1 intermediate and 11 finished dosage forms. Its veterinary API portfolio covers anthelmintics, ectoparasiticides, antiprotozoals, and phosphorus supplements, supported by custom synthesis and R&D capabilities.